Tumor associated macrophage in HPV+ tumors: Between immunosuppression and inflammation

Gorvel, Laurent; Olive, Daniel

doi:10.1016/j.smim.2022.101671

Cited by 19 publications

(16 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Macrophages are immune cells normally involved in several processes, namely, cell death, toxin clearance, wound healing, and others, acting as a “professional phagocytes” in both physiological and inflammatory/pathological conditions [ 46 ]. They are increasingly proposed as a therapeutic target in inflammatory and immune diseases [ 17 ] as well as in cancer [ 47 , 48 ]. The two prototypical macrophage phenotypes are M1, or classically activated macrophages with pro-inflammatory function, and M2, or alternatively activated macrophages with anti-inflammatory properties.…”

Section: Discussionmentioning

confidence: 99%

CB2 Receptor as Emerging Anti-Inflammatory Target in Duchenne Muscular Dystrophy

Argenziano

Pota

Paola

et al. 2023

IJMS

View full text Add to dashboard Cite

Duchenne Muscular Dystrophy (DMD) is a very severe X-linked dystrophinopathy. It is due to a mutation in the DMD gene and causes muscular degeneration in conjunction with several secondary co-morbidities, such cardiomyopathy and respiratory failure. DMD is characterized by a chronic inflammatory state, and corticosteroids represent the main therapy for these patients. To contradict drug-related side effects, there is need for novel and more safe therapeutic strategies. Macrophages are immune cells stringently involved in both physiological and pathological inflammatory processes. They express the CB2 receptor, one of the main elements of the endocannabinoid system, and have been proposed as an anti-inflammatory target in several inflammatory and immune diseases. We observed a lower expression of the CB2 receptor in DMD-associated macrophages, hypothesizing its involvement in the pathogenesis of this pathology. Therefore, we analyzed the effect of JWH-133, a CB2 receptor selective agonist, on DMD-associated primary macrophages. Our study describes the beneficial effect of JWH-133 in counteracting inflammation by inhibiting pro-inflammatory cytokines release and by directing macrophages’ phenotype toward the M2 anti-inflammatory one.

show abstract

Section: Discussionmentioning

confidence: 99%

CB2 Receptor as Emerging Anti-Inflammatory Target in Duchenne Muscular Dystrophy

Argenziano

Pota

Paola

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…[4][5][6] In recent years, extensive research has revealed the intricate connection between tumors and inflammation. [7][8][9][10] It has been found that the molecular and cellular mechanisms linking inflammation and cancer involve 2 pathways. The intrinsic pathway is initiated by genetic events that lead to tumor formation and subsequently activate inflammation-related programs, shaping the inflammatory microenvironment.…”

Section: The Relationship Between Tumors and Inflammationmentioning

confidence: 99%

Advances in systemic immune inflammatory indices in non-small cell lung cancer: A review

Mao,

Cao,

et al. 2024

Medicine

View full text Add to dashboard Cite

Lung cancer is one of the most prevalent cancers globally, with non-small cell lung cancers constituting the majority. These cancers have a high incidence and mortality rate. In recent years, a growing body of research has demonstrated the intricate link between inflammation and cancer, highlighting that inflammation and cancer are inextricably linked and that inflammation plays a pivotal role in cancer development, progression, and prognosis of cancer. The Systemic Immunoinflammatory Index (SII), comprising neutrophil, lymphocyte, and platelet counts, is a more comprehensive indicator of the host’s systemic inflammation and immune status than a single inflammatory index. It is widely used in clinical practice due to its cost-effectiveness, simplicity, noninvasiveness, and ease of acquisition. This paper reviews the impact of SII on the development, progression, and prognosis of non-small cell lung cancer.

show abstract

“…The activation process of macrophages is highly plastic, and depending on signals in the TME, macrophages can be polarized into M1 or M2 functional phenotypes ( 35 , 36 ). M1 macrophages secrete IFN, interleukin (IL), nitric oxide synthase, and reactive oxygen species to exert and enhance anti-tumor immunity ( 35 , 37 ). M2 macrophages are associated with high expression of IL-10, IL-1β and vascular endothelial growth factor (VEGF) in vivo , and form a beneficial survival environment for tumor cells by suppressing immunity and promoting tumor angiogenesis, invasion and distant metastasis ( 35 , 38 ).…”

Section: Tme In Lung Cancermentioning

confidence: 99%

Adjusting the dose of traditional drugs combined with immunotherapy: reshaping the immune microenvironment in lung cancer

Wang,

Du,

Jiang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Immunotherapy is currently the most promising clinical treatment for lung cancer, not only revolutionizing second-line therapy but now also approved for first-line treatment. However, its clinical efficiency is not high and not all patients benefit from it. Thus, finding the best combination strategy to expand anti-PD-1/PD-L1-based immunotherapy is now a hot research topic. The conventional use of chemotherapeutic drugs and targeted drugs inevitably leads to resistance, toxic side effects and other problems. Recent research, however, suggests that by adjusting the dosage of drugs and blocking the activation of mutational mechanisms that depend on acquired resistance, it is possible to reduce toxic side effects, activate immune cells, and reshape the immune microenvironment of lung cancer. Here, we discuss the effects of different chemotherapeutic drugs and targeted drugs on the immune microenvironment. We explore the effects of adjusting the dosing sequence and timing, and the mechanisms of such responses, and show how the effectiveness and reliability of combined immunotherapy provide improved treatment outcomes.

show abstract

Tumor associated macrophage in HPV+ tumors: Between immunosuppression and inflammation

Cited by 19 publications

References 94 publications

CB2 Receptor as Emerging Anti-Inflammatory Target in Duchenne Muscular Dystrophy

CB2 Receptor as Emerging Anti-Inflammatory Target in Duchenne Muscular Dystrophy

Advances in systemic immune inflammatory indices in non-small cell lung cancer: A review

Adjusting the dose of traditional drugs combined with immunotherapy: reshaping the immune microenvironment in lung cancer

Contact Info

Product

Resources

About